A public consortium of researchers is hoping to get permission to start a Phase I clinical trial of a new HIV vaccine early in the new year. [ + ]

Peptech managing director Stephen Kwik is accentuating the positives after Peptech reported an after-tax loss of $AU8.9 million loss in the 12 months to September, after a $AU32.7 million net profit in the previous year. [ + ]

Genetic Technologies' executive chairman Dr Mervyn Jacobson is surprised and disappointed by recent criticism of the deal he brokered with US genetic testing giant Myriad Genetics. [ + ]

Researchers from Monash University and the University of Sydney have designed a material containing holes one millionth of a millimetre wide that could provide a new mechanism for sensing molecules.

Prima BioMed subsidiary PanVax has entered into a research collaboration with the Institute Pasteur in France. [ + ]

The hunt for an anti-malaria vaccine is hotting up thanks to Australian researchers who have shown for the first time that T-cells can provide cell-based immunity in humans against the red blood cell stage of malaria. [ + ]

Antisense Therapeutics has raised $500,000 over its expected $4 million in an oversubscribed share placement that closed two days earlier than originally planned. [ + ]

The majority shareholder in Biota Holdings, Perth lawyer Farooq Khan, has resumed his campaign to force his way onto the listed biotech's board. [ + ]

A research network to provide GPs and other primary health care practitioners with support, mentoring and workshops to develop their research ideas is being rolled out around New South Wales.

The Executive Director of ANSTO, Professor Helen Garnett, said the recent launch of the Bragg Institute celebrated the evolution of ANSTO over the past 50 years into a world leader in the application, research and development of nuclear-based science and other technologies.

Diagnostics company Panbio has reached into the senior ranks of DuPont for a growth-oriented chief executive officer to oversee its next period of planned expansion. [ + ]

Melbourne biomedical company Circadian Technologies has announced it will fund a project at Melbourne University to develop an antisense therapy for Alzheimer's disease. [ + ]

The controversial seven-month freeze on Federal government R&D Start grants has thawed and AusIndustry is bracing itself for a pent-up flood of fresh applications. [ + ]

Virax has announced the successful completion of its Phase I/IIa trial for its HIV immune-based therapeutic VIR201, with the last of 34 patients completing the six-month series of injections and blood tests. [ + ]

The race to launch the first commercial DNA test kit identifying cattle which carry a gene associated with meat tenderness has been won by Australian agbiotech Genetic Solutions. [ + ]